BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/21/2020 6:56:33 AM | Browse: 1180 | Download: 2267
Publication Name World Journal of Gastroenterology
Manuscript ID 52516
Country Japan
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Minireviews
Article Title Update on quinolone-containing rescue therapies for Helicobacter pylori infection
Manuscript Source Invited Manuscript
All Author List Hideki Mori and Hidekazu Suzuki
ORCID
Author(s) ORCID Number
Hideki Mori http://orcid.org/0000-0001-8830-4671
Hidekazu Suzuki http://orcid.org/0000-0002-8994-6163
Funding Agency and Grant Number
Corresponding Author Hideki Mori, MD, PhD, Doctor, Doctor, Postdoctoral Fellow, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Herestraat 49 Box 701, Leuven 3000, Belgium. hideki.mori@kuleuven.be
Key Words Helicobacter pylori; Levofloxacin; Sitafloxacin; Moxifloxacin; gyrA; Vonoprazan
Core Tip The efficacies of 7-d levofloxacin or moxifloxacin, -containing regimens are becoming less effective in recent years due to the increasing antibiotic resistance, which necessitates 10-d or 14-d regimens or bismuth containing regimen are needed to achieve sufficient eradication rates. gyrA mutation is the most sensitive marker for predicting successful eradication in using quinolone-containing therapies. Thus, analysis of gyrA mutation before treatments is recommended. Seven-day sitafloxacin-amoxicillin-vonoprazan triple therapy is the best choice for third-line treatment at present.
Publish Date 2020-04-21 06:56
Citation Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol 2020; 26(15): 1733-1744
URL https://www.wjgnet.com/1007-9327/full/v26/i15/1733.htm
DOI https://dx.doi.org/10.3748/wjg.v26.i15.1733
Full Article (PDF) WJG-26-1733.pdf
Full Article (Word) WJG-26-1733.docx